CO2017002998A2 - Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 - Google Patents
Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1Info
- Publication number
- CO2017002998A2 CO2017002998A2 CONC2017/0002998A CO2017002998A CO2017002998A2 CO 2017002998 A2 CO2017002998 A2 CO 2017002998A2 CO 2017002998 A CO2017002998 A CO 2017002998A CO 2017002998 A2 CO2017002998 A2 CO 2017002998A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- compounds
- tetrahydronaphthalene derivatives
- mcl
- inhibit mcl
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043929P | 2014-08-29 | 2014-08-29 | |
| PCT/US2015/047472 WO2016033486A1 (en) | 2014-08-29 | 2015-08-28 | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017002998A2 true CO2017002998A2 (es) | 2017-07-19 |
Family
ID=54238507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0002998A CO2017002998A2 (es) | 2014-08-29 | 2017-03-28 | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 |
Country Status (41)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| AU2017300738A1 (en) | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| AU2018318692A1 (en) * | 2017-08-15 | 2020-03-12 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| SG10202106345VA (en) * | 2017-08-15 | 2021-07-29 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| EP3668878B1 (en) * | 2017-08-18 | 2025-05-21 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| MA54985A (fr) | 2018-03-05 | 2021-12-29 | Amgen Inc | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
| KR102732008B1 (ko) * | 2018-05-14 | 2024-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| JP2022506973A (ja) * | 2018-11-09 | 2022-01-17 | プレリュード セラピューティクス，インコーポレイティド | 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体 |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020147802A1 (en) * | 2019-01-18 | 2020-07-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as mcl-1 inhibitors |
| UY38700A (es) | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| JP7617861B2 (ja) * | 2019-06-21 | 2025-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の大環状阻害剤 |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| ES2987630T3 (es) | 2019-07-09 | 2024-11-15 | Janssen Pharmaceutica Nv | Derivados de espirociclos macrocíclicos como inhibidores de MCL-1 |
| EP3771469A1 (en) * | 2019-07-30 | 2021-02-03 | Amgen, Inc | Formulations and dosages for administering a compound that inhibits mcl1 protein |
| WO2021047616A1 (zh) * | 2019-09-12 | 2021-03-18 | 苏州亚盛药业有限公司 | 氧氮杂环庚烷类螺环化合物、中间体及其制备方法 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| AU2020379731A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) * | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| EP4107161A1 (en) * | 2020-02-21 | 2022-12-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3181214A1 (en) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
| MX2022013961A (es) | 2020-05-06 | 2022-11-30 | Amgen Inc | Sintesis de productos intermedios de sulfonamida. |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| JP7752635B2 (ja) * | 2020-05-06 | 2025-10-10 | アムジエン・インコーポレーテツド | ビニルアルコール中間体の合成 |
| TWI867217B (zh) * | 2020-05-06 | 2024-12-21 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| US20230219906A1 (en) | 2020-06-10 | 2023-07-13 | Janssen Pharmaceutica Nv | Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| IL300977A (en) | 2020-09-03 | 2023-04-01 | Amgen Inc | Removal of diol symmetry via nucleophilic aromatic substitution |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| CN116457334A (zh) * | 2020-11-19 | 2023-07-18 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| MX2023006144A (es) * | 2020-11-25 | 2023-06-06 | Amgen Inc | Alquenilacion enantioselectiva de aldehidos. |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| ES3026771T3 (en) | 2020-12-17 | 2025-06-12 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| AU2022267722A1 (en) | 2021-04-26 | 2023-12-14 | Janssen Pharmaceutica Nv | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN117651554A (zh) | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Mcl-1抑制剂与抗癌剂的组合 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| MX2024005928A (es) | 2021-11-16 | 2024-06-04 | Janssen Pharmaceutica Nv | 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1. |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CA3254998A1 (en) * | 2022-04-05 | 2023-10-12 | Amgen Inc | MCI-1 ANTAGONIST SALT AND SOLVATES FORMS |
| JP2025511331A (ja) * | 2022-04-05 | 2025-04-15 | アムジエン・インコーポレーテツド | Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| ES2400371T3 (es) * | 2005-07-07 | 2013-04-09 | Abbott Laboratories | Promotores de la apoptosis |
| JP5496877B2 (ja) | 2007-04-16 | 2014-05-21 | アッヴィ・インコーポレイテッド | ７−置換インドールＭｃｌ−１阻害薬 |
| WO2009016132A1 (en) * | 2007-07-27 | 2009-02-05 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| US8975286B2 (en) * | 2009-08-20 | 2015-03-10 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| MX2012004064A (es) * | 2009-10-08 | 2012-06-08 | Sanford Burnham Med Res Inst | Derivados apogosipolona como agentes antineoplasicos. |
| CA2787784A1 (en) * | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US9486422B2 (en) | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
| ES2657649T3 (es) * | 2012-03-29 | 2018-03-06 | The Regents Of The University Of Michigan | Inhibidores de Mcl-1 de molécula pequeña y sus usos |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
-
2015
- 2015-08-27 JO JOP/2015/0208A patent/JO3474B1/ar active
- 2015-08-28 KR KR1020177008470A patent/KR102466351B1/ko active Active
- 2015-08-28 HR HRP20190053TT patent/HRP20190053T1/hr unknown
- 2015-08-28 SM SM20190048T patent/SMT201900048T1/it unknown
- 2015-08-28 PT PT15772048T patent/PT3186259T/pt unknown
- 2015-08-28 PE PE2017000362A patent/PE20170892A1/es unknown
- 2015-08-28 HU HUE15772048A patent/HUE041806T2/hu unknown
- 2015-08-28 DK DK15772048.3T patent/DK3186259T3/en active
- 2015-08-28 ES ES15772048T patent/ES2706309T3/es active Active
- 2015-08-28 SI SI201530586T patent/SI3186259T1/sl unknown
- 2015-08-28 SG SG11201701525WA patent/SG11201701525WA/en unknown
- 2015-08-28 PL PL15772048T patent/PL3186259T3/pl unknown
- 2015-08-28 CN CN201580054328.4A patent/CN107001387B/zh active Active
- 2015-08-28 WO PCT/US2015/047472 patent/WO2016033486A1/en not_active Ceased
- 2015-08-28 UA UAA201702910A patent/UA118233C2/uk unknown
- 2015-08-28 CA CA2959615A patent/CA2959615C/en active Active
- 2015-08-28 EA EA201790492A patent/EA031223B1/ru not_active IP Right Cessation
- 2015-08-28 TW TW104128490A patent/TWI676628B/zh active
- 2015-08-28 AP AP2017009827A patent/AP2017009827A0/en unknown
- 2015-08-28 TN TN2017000067A patent/TN2017000067A1/en unknown
- 2015-08-28 MY MYPI2017000299A patent/MY176235A/en unknown
- 2015-08-28 ME MEP-2019-12A patent/ME03313B/me unknown
- 2015-08-28 CR CR20170116A patent/CR20170116A/es unknown
- 2015-08-28 MA MA40111A patent/MA40111B1/fr unknown
- 2015-08-28 MX MX2017002656A patent/MX379155B/es unknown
- 2015-08-28 RS RS20190094A patent/RS58276B1/sr unknown
- 2015-08-28 EP EP15772048.3A patent/EP3186259B1/en active Active
- 2015-08-28 TR TR2019/01312T patent/TR201901312T4/tr unknown
- 2015-08-28 LT LTEP15772048.3T patent/LT3186259T/lt unknown
- 2015-08-28 EP EP18187957.8A patent/EP3424931B1/en active Active
- 2015-08-28 US US14/839,149 patent/US9562061B2/en active Active
- 2015-08-28 AU AU2015308735A patent/AU2015308735B2/en active Active
- 2015-08-28 BR BR112017004209-6A patent/BR112017004209B1/pt active IP Right Grant
- 2015-08-28 ES ES18187957T patent/ES2777478T3/es active Active
- 2015-08-28 JP JP2017511734A patent/JP6502479B2/ja active Active
- 2015-08-31 UY UY0001036285A patent/UY36285A/es active IP Right Grant
- 2015-08-31 AR ARP150102791A patent/AR101729A1/es active IP Right Grant
-
2016
- 2016-12-12 US US15/376,456 patent/US10100063B2/en active Active
-
2017
- 2017-02-27 CL CL2017000469A patent/CL2017000469A1/es unknown
- 2017-02-28 PH PH12017500367A patent/PH12017500367B1/en unknown
- 2017-02-28 IL IL250843A patent/IL250843B/en active IP Right Grant
- 2017-03-10 ZA ZA2017/01763A patent/ZA201701763B/en unknown
- 2017-03-28 CO CONC2017/0002998A patent/CO2017002998A2/es unknown
-
2018
- 2018-03-07 IL IL257942A patent/IL257942B/en active IP Right Grant
- 2018-05-02 ZA ZA2018/02865A patent/ZA201802865B/en unknown
- 2018-09-05 US US16/121,750 patent/US10836779B2/en active Active
- 2018-09-06 US US16/123,030 patent/US10494381B2/en active Active
-
2019
- 2019-01-28 CY CY20191100117T patent/CY1121195T1/el unknown
- 2019-09-13 US US16/569,927 patent/US11001598B2/en active Active
-
2020
- 2020-10-21 US US17/075,864 patent/US11685747B2/en active Active
-
2023
- 2023-05-08 US US18/313,703 patent/US12024529B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| DOP2017000151A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| NI201500096A (es) | Compuesto químicos | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| ECSP18056196A (es) | Derivados de indano | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 |